Impax and GSK Announce Positive Topline Results of ASCEND-PD Phase III Study of IPX066 in Advanced Parkinson’s Disease
August 15 2011 - 7:00AM
Business Wire
Impax Pharmaceuticals, the branded products division of Impax
Laboratories, Inc. (NASDAQ: IPXL) and GlaxoSmithKline (GSK) today
announced top-line results of the ASCEND-PD Phase III clinical
study of IPX066 versus carbidopa-levodopa plus entacapone (CLE), in
patients with advanced Parkinson’s disease (PD). IPX066 is an
extended release capsule formulation of carbidopa-levodopa (CD-LD)
under investigation for the treatment of the motor symptoms of
PD.
The primary endpoint of this double blind crossover study was
the percentage of “off time” during waking hours as measured by
patient diary. “Off time” is the functional state when patients’
medication effect has worn off and there is a return of the motor
symptoms of PD. Patients entered the study with a baseline “off
time” of 36.1% (5.9 hours), and at the end of the randomized IPX066
treatment phase patients had “off time” of 24.0% (3.8 hours) during
waking hours compared to 32.5% (5.2 hours) for CLE (p
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From May 2024 to Jun 2024
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jun 2023 to Jun 2024